Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

January 27, 2023

Study Completion Date

May 8, 2025

Conditions
Hemophilia A
Interventions
BIOLOGICAL

valoctocogene roxaparvovec

Adeno-Associated Virus Vector-Mediated Gene Transfer of Human Factor VIII in Hemophilia A

Trial Locations (12)

43205

Nationwide Children's Hospital, Columbus

63110

Washington University School of Medicine, St Louis

95817

University of California Davis Health, Sacramento

Unknown

The Royal Adelaide Hospital, Adelaide

Royal Brisbane and Women's Hospital, Brisbane

Alfred Hospital, Melbourne

Fiona Stanley Hospital, Perth

Royal Prince Alfred Hospital, Sydney

Campinas University Clinical Hospital, Campinas

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo

Changhua Christian Medical Foundation Changhua Christian Hospital, Changhua

Taichung Veterans General Hospital, Taichung

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY